CANbridge is a biotechnology company focused on developing and commercializing rare disease therapeutics in China.
Location: China, Beijing
Employees: 11-50
Total raised: $176M
Founded date: 2012
Investors 5
| Date | Name | Website |
| - | General At... | generalatl... |
| - | Huangpu Ri... | hprpe.com |
| - | RA Capital... | racap.com |
| - | Qiming Ven... | qimingvent... |
| - | Qiming Ven... | qimingvc.c... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 05.12.2020 | Series E | $43M | - |
| 18.02.2020 | Series D | $98M | General At... |
| 23.05.2017 | Series B | $25M | - |
| 02.12.2014 | Series A | $10M | - |
Mentions in press and media 19
| Date | Title | Description |
| 13.08.2025 | China’s CANbridge Soars on USD12.7 Million Baheal Deal That May Boost Rare-Disease Drug Sales | (Yicai) Aug. 13 -- Shares in CANbridge Pharmaceuticals surged as much as 37.7 percent today after the Chinese rare-disease drug developer said pharmaceutical distributor Qingdao Baheal Medical will inject HKD100 million (USD12.7 million) in... |
| 16.10.2023 | CANbridge Announces Full Enrollment Reached in the Core Part of The CAN103 Phase 2 Trial for Gaucher Disease in China | BEIJING and BURLINGTON, Mass., Oct. 16, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transform... |
| 09.10.2023 | CANbridge Announces Marketing Approval of CAN108 (/LIVMARLI®) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS) | LIVMARLI is the First and Only Treatment Approved in Taiwan for Cholestatic Pruritus in ALGS LIVMARLI is approved for Cholestatic Pruritus in ALGS in the US, Canada, Europe, Mainland China, and other regions globally BEIJING and BURLINGTON,... |
| 06.09.2023 | CANbridge to Participate in Two Investor Conferences in September | BEIJING and BURLINGTON, Mass., Sept. 6, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (HKEX:1228), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transfo... |
| 31.08.2023 | CANbridge Announces Interim Financial Results and Corporate Updates for the Six Months Ended June 30, 2023 | BEIJING and CAMBRIDGE, Mass., Aug. 31, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals, Inc. ("CANbridge," stock code 1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development ... |
| 25.02.2021 | CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 25, 2021-- CANbridge Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing drug candidates in China and North Asia, and Puma Biotechnology, Inc. (Na... |
| 05.12.2020 | CANbridge Pharmaceuticals Completes $43 Million Series E Financing | - |
| 01.12.2020 | CANbridge Pharmaceuticals Closes $43 Million Series E Financing | BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals Inc., a company developing and commercializing innovative drugs to treat rare diseases and targeted cancers, announced that it has completed a US$43 million Series E... |
| 19.02.2020 | Canbridge nabs $98M to develop rare disease treatments | Chinese drugmaker Canbridge Pharmaceuticals has raised $98 million in a Series D led by General Atlantic and healthcare company WuXi AppTec. The Beijing-based startup maintains a partnership with WuXi Biologics, a sister company of WuXi App... |
| 18.02.2020 | CANbridge Pharmaceuticals Closes US$98M Series D Financing | CANbridge Pharmaceuticals Inc., a Beijing, China-based biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, completed a US$98m Series D financing. The round was ... |
Show more